Comparison of the response to Gefitinib between exon 19 deletions and exon 21 point mutations in patients with EGFR mutant Advanced NSCLC

Mohamed Esam ¹ , Dina Salem ² , Ghada Refaat ³ , Maha Yehia ⁴ , Amr Shafik ⁵

This email address is being protected from spambots. You need JavaScript enabled to view it.    Author mobile +201068510663

 

Introduction: Lung cancer has the highest incidence of all cancers and is the leading cause of cancer-related death worldwide. Activating mutations in the epidermal growth factor receptor (EGFR) gene in lung cancer were first identified in 2004.

Aim: The purpose of this study was to compare the response to Gefitinib between EGFR mutation exon 19 and EGFR mutation exon 21 in non- small cell lung cancer in Egyptian patients.

Methods: This is a retrospective analysis; the specimens of 60 patients with advanced NSCLC who had received gefitinib therapy from June 2017 to May 2020 were examined and correlated with survival.

Results revealed that, mean age was (59±12.7). 53.3% with exon 19 deletion and 46.7% exon 21 mutation. Median PFS of exon 19 was 12 months vs PFS of exon 21which was 10 months. No statistically significance regarding PFS between the two groups (P value = 0.12). OS data is still not mature.

Conclusion

There was no statistically significant difference found between exon 19 deletion and exon 21 mutation regarding PFS, OS data is emerging.